1. Struck MM (1994) Biopharmaceutical R and D success rates and development times: A new analysis provides benchmarks for the future.Bioffechnology12: 674–677
2. Talmadge JE (1998) Pharmacodynamic aspects of peptide administration biological response modifiers.Adv Drug Deliv Rev33: 241–252
3. Lee HJ (1995) Biopharmaceutical properties and pharmacokinetics of peptide and protein drugs. In: M Taylor, G Amidon (eds):Peptide-based drug design.American Chemical Society, Washington, D.C., 69–97
4. Arky R (1997)Physician’s desk reference.Medical Economics Company, Montvale, NJ
5. Zhi J, Teller SB, Satoh H, Koss-Twardy SG, Luke DR (1995) Influence of human serum albumin content in formulations on the bioequivalency of interferon alfa-2a given by subcutaneous injection in healthy male volunteers.J Clin Pharmacol35: 281–284